Leukemia

Protocols
14 protocols meet the specified criteria
Disease Site: Leukemia
Protocol No. Title
OCR11124 Treatment of Patients with Newly Diagnosed Standard Risk B - Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (B-LLY)
OCR11125 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
OCR11925 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies
OCR13966 Beat AML: Personalized Medicine for Acute Myeloid Leukemia Based on Functional Genomics
OCR13968 A phase I clinical trial to evaluate the maximally tolerated dose (MTD), dose limiting toxicities (DLTs) and safety profiles of increasing doses of lenalidomide after allo-HCT in AML and MDS subjects with minimal residual disease (MRD) detected by the CD34+ mixed chimerism analysis
OCR14209 iCare for Cancer Patients
OCR14651 A Phase Ib/II Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects with Resistant Acute Myeloid Leukemia (AML)
OCR14956 A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
OCR15238 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
OCR15352 A Phase 1/2, open label, multicentre study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymphocytic leukemia
OCR15563 Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
OCR15980 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
OCR16040 A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML) (IND: 129443)
OCR16161 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)